Compare PRAX & FSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | FSS |
|---|---|---|
| Founded | 2015 | 1901 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 6.6B |
| IPO Year | 2020 | 1994 |
| Metric | PRAX | FSS |
|---|---|---|
| Price | $282.31 | $118.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 4 |
| Target Price | ★ $572.13 | $131.75 |
| AVG Volume (30 Days) | ★ 475.2K | 413.4K |
| Earning Date | 05-08-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 0.46% |
| EPS Growth | N/A | ★ 14.57 |
| EPS | N/A | ★ 1.14 |
| Revenue | N/A | ★ $2,180,500,000.00 |
| Revenue This Year | N/A | $20.94 |
| Revenue Next Year | $7,758.26 | $6.79 |
| P/E Ratio | ★ N/A | $103.72 |
| Revenue Growth | N/A | ★ 17.14 |
| 52 Week Low | $37.25 | $100.43 |
| 52 Week High | $366.52 | $132.89 |
| Indicator | PRAX | FSS |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 63.08 |
| Support Level | $238.77 | $115.41 |
| Resistance Level | $342.62 | $119.69 |
| Average True Range (ATR) | 21.47 | 3.00 |
| MACD | 0.62 | 1.08 |
| Stochastic Oscillator | 39.34 | 95.75 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Federal Signal Corp designs and manufactures products and integrated solutions for municipal, governmental, industrial, and airport customers. It operates through two segments. The Environmental Solutions Group manufactures and supplies street sweeper vehicles, sewer cleaner and vacuum loader trucks, hydro-excavation trucks, high-performance water blasting equipment, dump truck bodies, and trailers. The Safety and Security Systems Group manufactures and supplies comprehensive systems and products used by law enforcement, fire rescue, and industrial sites to protect people and property. Its offerings include systems for community alerting and industrial communications. The company generates the majority of its revenue from the Environmental Solutions Group segment.